News

As a result of this sale, Sunesis and SARcode have terminated an earlier licensing agreement relating to this program, and Sunesis will forego future potential milestone payments and

The company raised approximately $15 million through equity contributions by existing investors, including ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Company, Unilever Technology

According to Teikoku, the transdermal formulation is a once-a-week patch that continuously delivers donepezil through the skin into the bloodstream. It will enable the number of doses to

Mindray Medical International, a developer, manufacturer and marketer of medical devices, has reported that GAAP net income was $31.6m, or $0.28 per diluted share, for the fourth quarter

MedX Health, a developer of drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, has received the CE Mark approval to market

pSivida, a drug delivery company, has completed enrollment of the BrachySil dose ranging clinical trial. The dose ranging study, conducted in the UK at Guy’s and St Thomas’

Quarter 4 2008 Results Revenues for quarter 4, 2008 amounted to $34.0 million compared to $35.7m for quarter 4, 2007, a decrease of 4.8%. This included a decrease

Anacor Pharmaceuticals, a biopharmaceutical company, has announced positive results from a Phase I clinical trial of AN2718, an investigational topical anti-fungal product candidate for the potential treatment of

John Brown is a PhD pharmacologist who has considerable management experience in the healthcare sector, most recently as chief executive officer of Acambis plc until 2004. Since that